Viracta Therapeutics, Inc.
VIRX
$0.0175
-$0.0038-17.84%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.41% | -28.50% | -14.78% | -14.72% | -60.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.36% | -22.98% | 13.67% | 17.17% | -30.99% |
| Operating Income | 18.36% | 22.98% | -13.67% | -17.17% | 30.99% |
| Income Before Tax | 16.25% | 21.26% | 25.13% | -33.30% | 28.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.25% | 21.26% | 25.13% | -33.30% | 28.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.25% | 21.26% | 25.13% | -33.30% | 28.99% |
| EBIT | 18.36% | 22.98% | -13.67% | -17.17% | 30.99% |
| EBITDA | 18.40% | 23.02% | -13.91% | -16.68% | 31.53% |
| EPS Basic | 18.11% | 22.95% | 26.77% | -31.69% | 30.79% |
| Normalized Basic EPS | 18.12% | 22.94% | 26.76% | -31.71% | 30.77% |
| EPS Diluted | 18.11% | 22.95% | 27.34% | -30.91% | 30.79% |
| Normalized Diluted EPS | 18.12% | 22.94% | 26.76% | -31.71% | 30.77% |
| Average Basic Shares Outstanding | 2.30% | 2.19% | 2.25% | 1.24% | 2.59% |
| Average Diluted Shares Outstanding | 2.30% | 2.19% | 2.25% | 1.24% | 2.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
